EGFR and head and neck squamous cell carcinoma: A combination of EGFR‐TKI gefitinib and GM‐CSF could recover T cell infiltration and enhance the efficacy of ICBs.[359] A similar phenotype was found in the HNSCC cells treated with nimotuzumab (an EGFR monoclonal antibody), which promotes DC maturation,[360] suggesting EGFR may inhibit DCs maturation and normal function.